Therapeutic Development Services
The development processes of primary mediastinal B-cell lymphoma (PMBCL) involve the complex interplay of genetic changes as well as the tumor microenvironment. At Protheragen, we seek to develop distinct therapeutics and exact animal models for preclinical assessment to streamline research regarding treatment solutions for PMBCL. Our services allow you to obtain the most reliable and relevant assistance expeditiously, thus facilitating your research goals.
Primary mediastinal B-cell lymphoma (PMBCL) is a unique subtype of diffuse large B-cell lymphoma (DLBCL) arising from the thymic medullary B-cells. It comprises 2-4% of all non-Hodgkin lymphomas, with an average onset age of 30-40 years and a female predominance (60-70% of cases). In contrast to classical DLBCL, PMBCL manifests as a bulky anterior mediastinal mass which can frequently lead to superior vena cava syndrome, dyspnea, or pericardial effusion.
Fig.1 Molecular pathways associated with primary mediastinal B-cell lymphoma (PMBCL). (Giulino-Roth, Lisa., 2018)
The features of primary mediastinal B-cell lymphoma (PMBCL) include gains of chromosome 9p and rearrangement of the JAK2 locus which results in the activation of the JAK-STAT signaling cascade. PMBCL pathogenesis also involves the dysregulated NF-kB and PI3K signaling pathways. The tumor microenvironment, including the interaction with mediastinal thymic epithelial cells, has a critical role in the advancement of the disease.
Fig.2 A popular signaling pathway in the research of primary mediastinal large B-cell lymphoma (PMBCL). (Chen, Huan, et al., 2021)
| Therapy | Mechanism of Action | Targets | NCT Number | Research Phase |
|---|---|---|---|---|
| Sintilimab |
|
PD-1 | NCT06412068 | Phase II |
| Pembro + CAR T-cell Therapy |
|
PD-1/CD19 | NCT05934448 | Phase II |
| Zanubrutinib + Tislelizumab |
|
BTK/PD-1 | NCT04705129 | Phase II |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
At Protheragen, our focus is providing cutting-edge diagnostic and therapeutic development services for primary mediastinal B-cell lymphoma (PMBCL), a complex lymphoproliferative disorder, with the utmost precision. We specially focus on the development of novel therapies from various molecular classes, which are painstakingly explored in sophisticated engineered models during preclinical research.
Therapeutic Development Services
As a leading provider of therapeutic development services, Protheragen is seeking to create novel therapies to treat primary mediastinal B-cell lymphoma (PMBCL) owing to the difficulties faced in this area.
Animal models are essential tools for understanding the biology of primary mediastinal B-cell lymphoma (PMBCL) and evaluating the efficacy and safety of potential therapies.
At Protheragen, we offer comprehensive pharmacodynamic (PD), pharmacokinetic (PK), and toxicology research services to support the development and regulatory approval of potential therapies for primary mediastinal B-cell lymphoma (PMBCL). If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
Myeloproliferative Disorders (MPDs)
Bone Marrow Failure Syndromes (BMFS)
